Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright

Key Points

• HC Wainwright forecasts Q1 2027 EPS of ($0.07) and FY2027 EPS of ($0.30), slightly weaker than the consensus of about ($0.27).
• OPKO reported Q1 EPS of ($0.07) which met estimates, but revenue of $124.2M missed the ~$130.5M consensus and was down 17.1% year‑over‑year, while Q2 guidance of $127M–$132M sits below Street expectations.
• Shares traded down roughly 8.3% after the report; analyst ratings are mixed (average "Hold" and $1.55 target) and institutional investors own about 64.6% of the stock.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, April 29th. HC Wainwright analyst Y. Chen expects that the biotechnology company will post earnings per share of ($0.07) for the quarter. The consensus estimate for OPKO Health's current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for OPKO Health's Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.30) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. During the same quarter last year, the business posted ($0.10) EPS. OPKO Health's revenue for the quarter was down 17.1% on a year-over-year basis.

Other equities research analysts also recently issued research reports about the company. Barrington Research reissued a "market perform" rating on shares of OPKO Health in a report on Wednesday. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of OPKO Health in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $1.55.

OPKO Health Trading Down 8.3%

NASDAQ OPK opened at $1.11 on Thursday. The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. OPKO Health has a twelve month low of $0.98 and a twelve month high of $1.60. The company has a market cap of $842.56 million, a price-to-earnings ratio of -3.70 and a beta of 1.49. The business's fifty day moving average is $1.18 and its 200 day moving average is $1.28.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Abel Hall LLC acquired a new position in OPKO Health during the 1st quarter worth about $38,000. OP Asset Management Ltd acquired a new position in OPKO Health during the 1st quarter worth about $1,257,000. Apella Capital LLC acquired a new position in OPKO Health during the 1st quarter worth about $34,000. SG Americas Securities LLC lifted its holdings in OPKO Health by 62.6% during the 1st quarter. SG Americas Securities LLC now owns 87,846 shares of the biotechnology company's stock worth $100,000 after buying an additional 33,824 shares during the period. Finally, World Investment Advisors lifted its holdings in OPKO Health by 63.8% during the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company's stock worth $84,000 after buying an additional 25,902 shares during the period. 64.63% of the stock is owned by institutional investors and hedge funds.

Key OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO reported clinical progress — initiated and completed the first-dose cohort of its MDX2301 Phase 1 trial (COVID-19 tetravalent bispecific antibody), and ModeX is advancing multiple clinical programs, which supports longer‑term pipeline value. OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
• Positive Sentiment: Pharma product sales rose in Q1, helping EPS come in line with estimates despite a smaller diagnostics base — a constructive signal for margin and product-mix improvement. OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
• Neutral Sentiment: Q1 EPS matched consensus at a ($0.07) loss — avoids an EPS shock but doesn’t provide upside momentum. Q1 Earnings Details
• Neutral Sentiment: Management set FY‑2026 revenue guidance at $530M–$560M (Street ~$545.5M) — a wide range that spans consensus, leaving interpretation mixed for investors. Opko outlines Q2 2026 revenue of $127M-$132M
• Negative Sentiment: Q1 revenue of $124.2M missed estimates (~$130.5M) and was materially down year‑over‑year, signaling near‑term revenue pressure tied to a smaller diagnostics base. Q1 Revenue Miss
• Negative Sentiment: Company guidance for Q2 revenue ($127M–$132M) is below the consensus (~$135.7M), which is likely to exert near‑term downward pressure on the share price. Q2 Guidance
• Negative Sentiment: HC Wainwright’s updated FY2027 estimate is weaker than consensus (forecasting ~$($0.30) vs. consensus ~$($0.27)), indicating analysts are trimming outlooks — another headwind for sentiment.

About OPKO Health

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.